Oxford study finds osteoarthritis is a single disease, reshaping treatment research

A major international study led by the Kennedy Institute of Rheumatology at the University of Oxford has found that osteoarthritis (OA), the most common form of arthritis worldwide, is a single disease driven by shared biological pathways rather than a collection of distinct disease subtypes.

Published in Nature Communications, the research is the largest molecular analysis of osteoarthritis tissue conducted so far. The findings address a long-standing question in osteoarthritis research and could influence the development of more targeted therapies for a condition that remains one of the leading causes of disability globally.

Why the findings matter

Osteoarthritis currently has no approved disease-modifying treatments. Researchers have long debated whether the condition consists of multiple biological subtypes, known as endotypes, which might explain why many clinical trials have failed to deliver effective therapies.

The new findings suggest that osteoarthritis shares a common molecular signature across patients, providing a clearer biological target for future drug development and clinical research.

“For decades, the field has debated whether OA is really a group of separate diseases, perhaps explaining why so many clinical trials have failed,” said Professor Tonia Vincent, lead investigator and Director of the Arthritis UK Centre for OA Pathogenesis at the Kennedy Institute of Rheumatology. “We revealed no evidence of distinct disease subtypes, instead, we’ve demonstrated that at the molecular level OA is a single disease with a common set of ‘core’ pathways, mostly related to tissue injury and repair.”

Largest analysis of osteoarthritis tissue

The research was conducted through the STEpUP OA (Synovial fluid To detect Endotypes by Unbiased Proteomics in OA) project, which brought together scientists from Europe, Canada and the United Kingdom, along with industry and charity partners.

Researchers analysed synovial fluid, the lubricating fluid found in knee joints, from more than 1,300 people with established knee osteoarthritis. Using the SomaScan v4.1 proteomics platform developed by SomaLogic, the team measured more than 7,000 proteins in each sample.

Proteomics is the large-scale study of proteins and helps researchers understand biological processes occurring within tissues and organs.

The investigators compared molecular patterns across samples to determine whether osteoarthritis consists of several biologically distinct forms or a single disease process.

The analysis found no evidence of separate molecular subtypes. Instead, researchers identified a common set of biological pathways linked primarily to tissue injury and repair.

Risk factors shape disease variation

While the study found a shared molecular fingerprint for osteoarthritis, researchers also identified biological differences associated with known risk factors such as obesity, biological sex and age.

Among participants with obesity, the team detected additional inflammatory signals. The researchers said these signals were not driven by immune-cell inflammation of the type seen in rheumatoid arthritis. Instead, they appeared to reflect a tissue injury response associated with mechanical stress within the joint.

The findings suggest that risk factors may influence how quickly osteoarthritis progresses and how patients respond to treatment, even though the underlying disease biology remains shared.

According to the researchers, these differences could help improve patient selection in clinical trials and support more precise treatment strategies.

Resource for future drug development

Dr Thomas Perry, senior postdoctoral molecular epidemiologist at the Kennedy Institute of Rheumatology and first author of the study, said the findings provide a framework for future therapeutic development.

“This work provides a clear map of the molecular landscape of OA and offers a valuable resource for researchers and pharmaceutical companies,” Perry said. “It will allow us to match patients to therapies much more precisely, a crucial step towards developing long-awaited treatments that slow or halt disease progression.”

The STEpUP OA dataset has been made available to the wider research community. Scientists can use the resource to investigate biological pathways, identify patient groups most likely to benefit from specific treatments and design more targeted clinical trials.

Researchers said this approach could help reduce development costs and improve the likelihood of success in future osteoarthritis studies.

Implications for patients

Professor Lucy Donaldson, Director of Research at Arthritis UK, said a better understanding of osteoarthritis biology could support the development of more personalised treatments.

“People experience OA differently, we know for example that peri-menopausal women face higher risk, and that some people see their symptoms progress far more quickly than others,” Donaldson said. “Understanding the mechanisms of OA is a crucial step towards understanding why the condition varies so much between individuals.”

The study also highlights the role of lifestyle-related risk factors. Researchers noted that obesity was associated with amplified inflammatory signals within the joint, reinforcing the importance of weight management in osteoarthritis care.

For patients, the findings offer evidence that osteoarthritis is underpinned by well-defined biological pathways rather than multiple diseases with different underlying biology.

“By showing that OA biology is shared across patients, we now have a much clearer target,” Vincent said. “It means we can focus on therapies that address this core pathway and adapt them for people with different risk factors. This is a major step towards development of effective treatments.”